创胜集团 - 全整合型国际化生物制药公司

创胜集团, 生物药, 抗体, 药物研发

创胜集团 - 全整合型国际化生物制药公司

联系我们 EN

媒体报道

2020 年 11 月 07 日
创胜集团与默克战略技术合作,共推治疗性蛋白药物连续流工艺

11月7日,在第三届中国国际进口博览会上,创胜集团与默克宣布战略技术合作,共同推进治疗性蛋白药物的连续流生产。

2020 年 07 月 16 日
创胜集团首席运营官叶峰博士——借工艺设计助国内创新药突围

继日前Claudin18.2人源化单克隆抗体新药TST001,获美国食药监局和中国药监局针对转移性实体瘤患者进行临床试验许可后,7月1日,创胜集团宣布在美国开展的I期临床研究已完成首例患者给药。

2020 年 06 月 08 日
Transcenta to begin HK IPO preparations end-2020; in USD 100m crossover funding talks

Transcenta, a privately-owned, US-China-based integrated biopharmaceutical company, is in the process of marching ahead with an initial public offering (IPO) after receiving a USD 100m Series B+ funding this January, according to company Chief Executive Ofcer Dr. Xueming Qian and Executive Chairman Dr. Jonathan Zhao. The two co-founders said that the company is in crossover funding talks with potential investors, and aims to kick off the Hong Kong IPO at the end of this year.

2020 年 01 月 13 日
Temasek-backed Transcenta mulls HK-China dual IPO listing

After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.

2020 年 01 月 09 日
Jan. 8 Financial Quick Takes:

Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

2019 年 08 月 06 日
Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019

“I did not want to work on an antibody similar to the dozens already in clinical trials, I wanted to find a differentiator!”

1 2